Mga Batayang Estadistika
| CIK | 1826667 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TriSalus Life Sciences, Inc. - Equity Warrant
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or orga |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 12, 2025 |
Sign-on Bonus Agreement, by and between the Company and David Patience, dated May 27, 2025 Exhibit 10.2 SIGN-ON BONUS AGREEMENT THIS SIGN-ON BONUS AGREEMENT (“Agreement”) is entered into on the 1st day of July, 2025 (the “Effective Date”), by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and Mr. David Patience (the “Employee”). NOW, THEREFORE, in consideration of the mutual promises made below, the parties agree as follows: 1.Sign-On Bonus. The Compan |
|
| August 12, 2025 |
Executive Employment Agreement, by and between the Company and David Patience, dated May 27, 2025 Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of July 1, 202 |
|
| August 12, 2025 |
Consulting Agreement, by and between the Company and David Patience, dated June 2, 2025 Exhibit 10.3 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into effective as of Monday, June 2, 2025 (the “Effective Date”) by and betwe |
|
| August 12, 2025 |
TriSalus Life Sciences Second Quarter 2025 Results and Provides Updated 2025 Guidance Company delivers $11. |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or orga |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Series A Convertible Preferred Stock (Title of Class of Securities) Not Applicable (CUSIP Number of Class of Securitie |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organi |
|
| July 24, 2025 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK OF TRISALUS LIFE SCIENCES, INC. Pursuant to Section 242 of the Delaware General Corporation Law This Certificate of Amendment to the Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock (the “Amendment”) is dated as of July 24, 2 |
|
| July 24, 2025 |
EXHIBIT 99.1 TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock WESTMINSTER, CO — July 24, 2025 — TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company focused on improving outcomes for patients with solid tumors, announced the completion of its previously disclosed exchange offer and consent solicita |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Series A Convertible Preferred Stock (Title of Class of Securities) Not Applicable (CUSIP Number of Class of Securitie |
|
| July 11, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 11, 2025 Registration No. 333-288250 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of i |
|
| June 23, 2025 |
Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Shares of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 |
|
| June 23, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) TriSalus Life Sciences, Inc. |
|
| June 23, 2025 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Shares of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTE |
|
| June 23, 2025 |
Form of Notice of Guaranteed Delivery. Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY OF SHARES OF PREFERRED STOCK OF TRISALUS LIFE SCIENCES, INC. Pursuant to the Prospectus/Offer to Exchange dated July 23, 2025 Instructions for Use Unless defined herein, terms used in this Notice of Guaranteed Delivery shall have definitions set forth in the Prospectus/Offer to Exchange dated July 23, 2025. This Notice of Guaranteed Delivery, or one subst |
|
| June 23, 2025 |
As filed with the U.S. Securities and Exchange Commission on [ ], 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorporation or organization |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Series A Convertible Preferred Stock (Title of Class of Securities) Not Applicable (CUSIP Number of Class of Securities) Mary Szela Chie |
|
| June 23, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form TO (Form Type) TriSalus Life Sciences, Inc. |
|
| June 23, 2025 |
Form of Letter of Transmittal and Consent. Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer To Exchange Shares of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TIME, ON JULY 23, 2025, OR SUCH LAT |
|
| June 23, 2025 |
EXHIBIT 99.1 TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure WESTMINSTER, CO — June 23, 2025 — TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics |
|
| June 23, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organi |
|
| June 16, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organi |
|
| June 6, 2025 |
TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 June 6, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Nicholas O’Leary Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 May 30, 2025 File No. 333-287696 Ladies and Gentlemen: |
|
| May 30, 2025 |
As filed with the U.S. Securities and Exchange Commission on May 30, 2025 As filed with the U.S. Securities and Exchange Commission on May 30, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorporation or organizat |
|
| May 30, 2025 |
EXHIBIT 99.1 TriSalus Life Sciences Announces Chief Financial Officer Transition with Appointment of David B. Patience David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance, to serve as acting CFO during transition period Denver, CO – May |
|
| May 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organiz |
|
| May 30, 2025 |
Exhibit 4.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 2, 2025, is entered into by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms |
|
| May 30, 2025 |
EXHIBIT 10.1 AGREEMENT AND RELEASE This Agreement and Release ("Agreement") is made by and between TriSalus Life Sciences, Inc. (the "Company"), and James Young (the "Executive") (collectively referred to herein as the "Parties" and each a "Party"). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement (as defined below). WHEREAS, th |
|
| May 30, 2025 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) TriSalus Life Sciences, Inc. |
|
| May 28, 2025 |
TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 May 28, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Conlon Danberg Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 April 28, 2025 File No. 333-286797 Ladies and Gentlemen: |
|
| May 15, 2025 |
TriSalus Life Sciences First Quarter 2025 Results and Provides Updated 2025 Guidance Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET DENVER – May 15, 2025 - TriSalus Life Sciences, Inc. |
|
| May 15, 2025 |
EXHIBIT 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of April 30, 2025 by and among TRISALUS OPERATING LIFE SCIENCES, INC., a Delaware corporation (the “Borrower”), TRISALUS LIFE SCIENCES, INC., a Delaware corporation (the “Parent”), the Lenders party hereto (the “Lenders”) and ORBIMED ROYALTY & CREDIT OPPORTUNIT |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 15, 2025 |
EXHIBIT 10.2 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT No. 1 TO STRATEGIC COLLABORATION AGREEMENT This Amendment No. 1 to the March 2, 2021 Strategic Collaboration Agreement ( "Amendment 1") is effective as of February 25, 2025 ("Amendment Effective Date" |
|
| May 15, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organiz |
|
| April 30, 2025 |
Form of Registration Rights Agreement. Exhibit 10.2 Final Form REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April [●], 2025, is entered into by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capi |
|
| April 30, 2025 |
Form of Registration Rights Agreement Exhibit 10.2 Final Form REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April [●], 2025, is entered into by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capi |
|
| April 30, 2025 |
Form of Tender and Support Agreement, by and between the Company and Supporting Stockholders. Exhibit 10.3 Execution Version TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the persons listed on Schedule A hereto (collectively, the “Preferred Stock Holders,” and each a “Preferred Stock Holder”). WITNESSETH: WHEREAS, as of the date hereof, |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 30, 2025 |
Exhibit 99.1 TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Sup |
|
| April 30, 2025 |
Exhibit 99.1 TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Sup |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ |
|
| April 30, 2025 |
TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 April 30, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Margaret Sawicki Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 Filed April 25, 2025 File No. 333-286779 Ladies and G |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ |
|
| April 30, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliver |
|
| April 30, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and deliver |
|
| April 30, 2025 |
Exhibit 10.3 Execution Version TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of April 30, 2025, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the persons listed on Schedule A hereto (collectively, the “Preferred Stock Holders,” and each a “Preferred Stock Holder”). WITNESSETH: WHEREAS, as of the date hereof, |
|
| April 28, 2025 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) TriSalus Life Sciences, Inc. |
|
| April 28, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 85-3009869 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 (State or other jurisdiction of incorporation or organiz |
|
| April 28, 2025 |
Exhibit 4.3 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), is made and entered into as of December 12, 2024, between TriSalus Life Sciences, Inc., a Delaware corporation, with offices at 6272 West 91ST Avenue, Westminster, CO 80031 (the “Company”) and each of those persons and entities, severally and not jointly, whose names are set forth on the Schedule of Pu |
|
| April 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) TriSalus Life Sciences, Inc. |
|
| April 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TriSalus Life Sciences, Inc. |
|
| April 25, 2025 |
As filed with the Securities and Exchange Commission on April 25, 2025 As filed with the Securities and Exchange Commission on April 25, 2025 Registration No. |
|
| April 25, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 25, 2025 As filed with the U.S. Securities and Exchange Commission on April 25, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 85-3009869 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 (State or other jurisdiction of incorporation or org |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ |
|
| April 15, 2025 |
EXHIBIT 4.10 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATIO |
|
| April 15, 2025 |
EXHIBIT 10.22 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of Monday, January 6, 2 |
|
| April 15, 2025 |
Amended and Restated Non-Employee Director Compensation Policy. EXHIBIT 10.13 TriSalus Life Sciences, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to TriSalus Life Sciences, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy |
|
| April 15, 2025 |
EXHIBIT 10.26 FIRST AMENDMENT TO CREDIT AGREEMENT AND REGISTRATION RIGHTS AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is made and entered into as of March 20, 2025 by and among TRISALUS OPERATING LIFE SCIENCES, INC., a Delaware corporation (the “Borrower”), TRISALUS LIFE SCIENCES, INC., a Delaware corporation (the “Parent”), the Lenders p |
|
| April 15, 2025 |
EXHIBIT 4.11 WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATIO |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-398 |
|
| April 15, 2025 |
EXHIBIT 10.31 AMENDMENT NO. 2 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 2 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of Monday, January 6, 2025 (the “Amendment Effective Date”) by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and Richard Marshak, an individual (the “Execut |
|
| April 15, 2025 |
EXHIBIT 10.30 AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of Wednesday, January 24, 2024 (the “Amendment Effective Date”) by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and Richard Marshak, an individual (the “Ex |
|
| April 15, 2025 |
TriSalus Life Sciences, Inc. Insider Trading Policy AMENDED AND RESTATED TRISALUS LIFE SCIENCES, INC. INSIDER TRADING POLICY Adopted by the Board of Directors: January 24, 2024 Effective: January 24, 2024 Policy Principles •Employees, directors, officers and designated consultants (each a “Covered Person,” and collectively, “Covered Persons”) of TriSalus Life Sciences, Inc. and its subsidiaries (together, the “Company”) (or any other person or enti |
|
| April 15, 2025 |
EXHIBIT 21.1 List of Subsidiaries of TriSalus Life Sciences, Inc. Name Jurisdiction of Incorporation or Organization TriSalus Operating Life Sciences, Inc. Delaware |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR o For Period Ended: December 31, 2023 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q For the Transition |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or organ |
|
| March 27, 2025 |
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update •Revenues of $8. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or or |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or or |
|
| February 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or org |
|
| February 3, 2025 |
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed DENVER, Colo. |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or org |
|
| January 23, 2025 |
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call •4Q Sales of approximately $8. |
|
| January 23, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporation or org |
|
| January 8, 2025 |
by and between the Company and James Young, Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution Version EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of January 6, |
|
| January 8, 2025 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution Version AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Ag |
|
| January 8, 2025 |
Exhibit 99.1 TriSalus Announces Leadership Changes James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Operations DENVER – January 8, 2025 - TriSalus Life Sciences, Inc., (Nasdaq: TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery tech |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2025 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 4, 2024 |
TLSI / TriSalus Life Sciences, Inc. / PALLOTTA JAMES J - SC 13G Passive Investment SC 13G 1 tm2430131d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TRISALUS LIFE SCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 89680M101 (CUSIP Number) November 26, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 14, 2024 |
TriSalus Life Sciences Condensed Consolidated Statement of Operations (unaudited, in thousands) Exhibit 99.1 TriSalus Reports Q3 2024 Financial Results and Provides Business Update · Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year · Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 · Launched TriNav® LV In |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 6, 2024 |
TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 November 6, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Robert Augustin Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-3 File No. 333-282882 Ladies and Gentlemen: TriSalus L |
|
| November 6, 2024 |
As filed with the U.S. Securities and Exchange Commission on November 6, 2024. As filed with the U.S. Securities and Exchange Commission on November 6, 2024. Registration No. 333-276070 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 29, 2024 |
As filed with the U.S. Securities and Exchange Commission on October 29, 2024. S-3 1 tm2426916d4s3.htm FORM S-3 As filed with the U.S. Securities and Exchange Commission on October 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of inco |
|
| October 29, 2024 |
As filed with the U.S. Securities and Exchange Commission on October 29, 2024. As filed with the U.S. Securities and Exchange Commission on October 29, 2024. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j |
|
| October 29, 2024 |
As filed with the U.S. Securities and Exchange Commission on October 29, 2024. As filed with the U.S. Securities and Exchange Commission on October 29, 2024. Registration No. 333-276070 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j |
|
| October 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) TriSalus Life Sciences, Inc. |
|
| October 29, 2024 |
Exhibit 4.10 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS |
|
| October 29, 2024 |
Exhibit 4.10 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS |
|
| October 29, 2024 |
Exhibit 4.10 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS |
|
| October 29, 2024 |
Exhibit 4.10 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS |
|
| October 29, 2024 |
Exhibit 4.11 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS |
|
| October 29, 2024 |
Exhibit 4.11 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS |
|
| October 29, 2024 |
Exhibit 4.11 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS |
|
| October 29, 2024 |
As filed with the U.S. Securities and Exchange Commission on October 29, 2024 As filed with the U.S. Securities and Exchange Commission on October 29, 2024 Registration No. 333-280197 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 on FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 85-3009869 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 (S |
|
| October 29, 2024 |
Exhibit 4.11 Execution Version WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TriSalus Life Sciences Inc. (Name of Issuer) Common stock (Title of Class of Securities) 89680M101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| August 15, 2024 |
5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 7 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem |
|
| August 15, 2024 |
130,805 Shares of Common Stock Issuable Upon Exercise of Warrant Filed pursuant to Rule 424(b)(3) Registration No. 333-280197 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated June 14, 2024) 130,805 Shares of Common Stock Issuable Upon Exercise of Warrant This prospectus supplement supplements the prospectus dated June 14, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280197). This prospectus supplement is bei |
|
| August 15, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 7 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 15, 2024 |
TriSalus Life Sciences Condensed Consolidated Statement of Operations (unaudited, in thousands) Exhibit 99.1 TriSalus Reports Q2 2024 Financial Results and Business Update · Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods · Reported gross margin of 88% in Q2 2024 and 86% for six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periods · Announces |
|
| August 14, 2024 |
130,805 Shares of Common Stock Issuable Upon Exercise of Warrant Filed pursuant to Rule 424(b)(3) Registration No. 333-280197 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated June 14, 2024) 130,805 Shares of Common Stock Issuable Upon Exercise of Warrant This prospectus supplement supplements the prospectus dated June 14, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280197). This prospectus supplement is bei |
|
| August 14, 2024 |
SECOND AMENDMENT TO LEASE OF SPACE 7/17/2024 This Second Amendment to Lease of Space (“Amendment”) is made this day of July, 2024, between BPAZ HOLDINGS 14, LLC, a Delaware limited liability company (“Landlord”), and TRISALUS LIFE SCIENCES, INC. |
|
| August 14, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 6 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001 |
|
| August 14, 2024 |
EXHIBIT 4.7 DESCRIPTION OF OUR SECURITIES Explanatory Note TriSalus Life Sciences, Inc., a Delaware corporation (“TriSalus,” the “Company,” “we,” “us” or “our”), was originally known as MedTech Acquisition Corporation (“MTAC”), a special purpose acquisition company. On August 10, 2023, MTAC consummated a business combination with privately held TriSalus Life Sciences, Inc. pursuant to that certain |
|
| August 14, 2024 |
5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 6 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| July 1, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which |
|
| July 1, 2024 |
130,805 Shares of Common Stock Issuable Upon Exercise of Warrant Filed pursuant to Rule 424(b)(3) Registration No. 333-280197 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated June 14, 2024) 130,805 Shares of Common Stock Issuable Upon Exercise of Warrant This prospectus supplement supplements the prospectus dated June 14, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-280197). This prospectus supplement is bei |
|
| July 1, 2024 |
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation Exhibit 99.1 TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation WESTMINSTER, CO - (BUSINESS WIRE) – July 1, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the clo |
|
| July 1, 2024 |
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation Exhibit 99.1 TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation WESTMINSTER, CO - (BUSINESS WIRE) – July 1, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the clo |
|
| July 1, 2024 |
5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 27, 2024 |
Exhibit 99.1 TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants WESTMINSTER, CO - (BUSINESS WIRE) – June 26, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreat |
|
| June 27, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGREEMENT This Amendment (this “Amendment”) is made as of June 26, 2024, by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”) (f/k/a MedTech Acquisition Corporation (“MTAC”)), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that cert |
|
| June 27, 2024 |
Exhibit 99.1 TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants WESTMINSTER, CO - (BUSINESS WIRE) – June 26, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreat |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 27, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 TO WARRANT AGREEMENT This Amendment (this “Amendment”) is made as of June 26, 2024, by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”) (f/k/a MedTech Acquisition Corporation (“MTAC”)), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that cert |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Warrants to Acquire Shares of Common Stock (Title of Class of Securities) 89680M119 (CUSIP Number of Class of Securiti |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 26, 2024 |
424B3 1 tm2415050-3424b3.htm 424B3 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-279691 PROSPECTUS/OFFER TO EXCHANGE TRISALUS LIFE SCIENCES, INC. Offer to Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND WITHDRAWAL RIGHTS WILL EX |
|
| June 20, 2024 |
TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 June 20, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Conlon Danberg Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-1 File No. 333-280197 Ladies and Gentlemen: TriSalus Life |
|
| June 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) TriSalus Life Sciences, Inc. |
|
| June 14, 2024 |
As filed with the U.S. Securities and Exchange Commission on June 14, 2024 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 14, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorpo |
|
| May 24, 2024 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit 99.3 LETTER TO BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN S |
|
| May 24, 2024 |
Exhibit 99.1 TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants DENVER - (BUSINESS WIRE) - May 24, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) TriSalus Life Sciences, Inc. |
|
| May 24, 2024 |
Exhibit 99.1 TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants DENVER - (BUSINESS WIRE) - May 24, 2024 - TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced |
|
| May 24, 2024 |
Form of Notice of Guaranteed Delivery. Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY OF WARRANTS OF TRISALUS LIFE SCIENCES, INC. Pursuant to the Prospectus/Offer to Exchange dated May 24, 2024 Instructions for Use Unless defined herein, terms used in this Notice of Guaranteed Delivery shall have definitions set forth in the Prospectus/Offer to Exchange dated May 24, 2024. This Notice of Guaranteed Delivery, or one substantially in the for |
|
| May 24, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO (Form Type) TriSalus Life Sciences, Inc. |
|
| May 24, 2024 |
5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem |
|
| May 24, 2024 |
Form of Tender and Support Agreement, by and between the Company and Supporting Stockholders. Exhibit 10.29 FORM OF TENDER AND SUPPORT AGREEMENT TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of [·], 2024, by and among TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the persons listed on Schedule A hereto (collectively, the “Warrant Holders,” and each a “Warrant Holder”). WITNESSETH: WHEREAS, as of the date hereof, each Warrant Holder is the ben |
|
| May 24, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which |
|
| May 24, 2024 |
As filed with the U.S. Securities and Exchange Commission on May 24, 2024 Table of Contents As filed with the U.S. Securities and Exchange Commission on May 24, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 3841 85-3009869 (State or other jurisdiction of incorpor |
|
| May 24, 2024 |
Form of Dealer Manager and Solicitation Agent Agreement. Exhibit 10.28 TRISALUS LIFE SCIENCES, INC. Dealer Manager and Solicitation Agent Agreement May 24, 2024 Oppenheimer & Co. Inc, as Dealer Manager 85 Broad Street, 23rd Floor New York, NY 10004 Ladies and Gentlemen: TriSalus Life Sciences, Inc., a Delaware corporation (the “Company” or “we”), plans to make an offer (such offer as described in the Prospectus (as defined below), together with the rela |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TRISALUS LIFE SCIENCES, INC. (Name of Subject Company and Filing Persons (Issuer)) Warrants to Acquire Shares of Common Stock (Title of Class of Securities) 89680M119 (CUSIP Number of Class of Securities) Mary Szela Chi |
|
| May 24, 2024 |
Form of Letter to Clients of Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees. Exhibit 99.4 LETTER TO CLIENTS OF BROKERS, DEALERS, COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer To Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M. |
|
| May 24, 2024 |
Exhibit 99.1 LETTER OF TRANSMITTAL AND CONSENT Offer To Exchange Warrants to Acquire Shares of Common Stock of TriSalus Life Sciences, Inc. for Shares of Common Stock of TriSalus Life Sciences, Inc. and Consent Solicitation THE OFFER AND CONSENT SOLICITATION (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., EASTERN STANDARD TIME, ON JUNE 25, 2024, OR SUCH LATER T |
|
| May 15, 2024 |
REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 30, 2024, by and between TriSalus Life Sciences, Inc. |
|
| May 15, 2024 |
WARRANT CERTIFICATE THIS WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT C |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 |
|
| May 15, 2024 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 15, 2024 |
5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem |
|
| May 15, 2024 |
TriSalus Reports Q1 2024 Financial Results and Business Update Exhibit 99.1 TriSalus Reports Q1 2024 Financial Results and Business Update · Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 · Reported Gross Margin of 85% in 1Q24 · Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion System growth initiatives · Announced the appointment of Liselotte Hyveled to the Board of Directors · Full year sales growth ex |
|
| May 15, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which |
|
| May 7, 2024 |
5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem |
|
| May 7, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 TRISALUS LIFE SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 TRISALUS LIFE SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 30, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated April 16, 2024) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which |
|
| April 30, 2024 |
5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated April 16, 2024) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated April 16, 2024 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and supplem |
|
| April 30, 2024 |
Exhibit 99.1 TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives · $25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the achievement of certain revenue thresholds · Capital from the transaction is expected to support execution of strategic expansion and f |
|
| April 17, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 16, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on April 16, 2024. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or oth |
|
| April 17, 2024 |
As filed with the U.S. Securities and Exchange Commission on April 16, 2024. Table of Contents As filed with the U.S. Securities and Exchange Commission on April 16, 2024. Registration No. 333-276070 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or oth |
|
| April 16, 2024 |
Letter from KPMG LLP to the SEC, dated April 15, 2024. Exhibit 16.1 April 15, 2024 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for TriSalus Life Sciences, Inc. (the Company) and, under the date of April 11, 2024, we reported on the consolidated financial statements of the Company as of and for the years ended December 31, 2023 and 2022. On April 12, 2024, we were dismissed. W |
|
| April 16, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATE SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-398 |
|
| April 11, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TriSalus Life Sciences, Inc. |
|
| April 11, 2024 |
TriSalus Life Sciences, Inc. Incentive Compensation Recoupment Policy TriSalus Life Sciences, Inc. Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) of TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recovera |
|
| April 11, 2024 |
AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into as of Wednesday, January 24, 2024 (the “Amendment Effective Date”) by and between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and Richard Marshak, an individual (the “Executive”) (the |
|
| April 11, 2024 |
As filed with the Securities and Exchange Commission on April 11, 2024 As filed with the Securities and Exchange Commission on April 11, 2024 Registration No. |
|
| April 11, 2024 |
Exhibit 4.1 Description of Securities Explanatory Note TriSalus Life Sciences, Inc., a Delaware corporation (“TriSalus,” the “Company,” “we,” “us” or “our”), was originally known as MedTech Acquisition Corporation (“MTAC”), a special purpose acquisition company. On August 10, 2023, MTAC consummated a business combination with privately held TriSalus Life Sciences, Inc. pursuant to that certain Agr |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| April 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| April 1, 2024 |
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update Exhibit 99.1 TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update · Reported revenues of $5.7 million in 4Q23, up 77% over prior year · Full year revenues of $18.5 million, up 49% over prior year · Gross Margin of 90% in 4Q23 and 86% for full year · CMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS code · Real-world data published on TriNa |
|
| March 12, 2024 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 25, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated December 26, 2023) Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus supplement supplements the prospectus dated December 26, 2023 (the “Prospectus”), |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 25, 2024 |
5,859,375 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus Dated December 26, 2023) 5,859,375 Shares of Common Stock This prospectus supplement supplements the prospectus dated December 26, 2023 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-276070). This prospectus supplement is being filed to update and s |
|
| January 5, 2024 |
1 TriSalus Life Sciences January 2024 Exhibit 99.1 1 TriSalus Life Sciences January 2024 2 Disclaimer Certain statements in this presentation may constitute “forward looking statements” within the meaning of applicable United S tat es federal securities laws. Forward looking statements include, but are not limited to, statements regarding TriSalus’s expectations, hopes, beliefs, intentions or strategies regarding the future including, |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 TRISALUS LIFE SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 26, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-274292 PROSPECTUS Up to 13,215,112 Shares of Common Stock Issuable Upon Exercise of Warrants Up to 36,772,040 Shares of Common Stock and Up to 5,933,333 Warrants to Purchase Common Stock This prospectus relates to the issuance by us of an aggregate of up to 13,215,112 shares of our common stock, $0.0001 par value per share ( |
|
| December 26, 2023 |
5,859,375 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-276070 PROSPECTUS 5,859,375 Shares of Common Stock This prospectus relates to the offer and sale, from time to time, by the selling securityholder identified in this prospectus (the “Selling Securityholder”), or its permitted transferees, of up to 5,859,375 shares of our common stock, $0.0001 par value per share (“Common Sto |
|
| December 21, 2023 |
TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 December 21, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Juan Grana Re: TriSalus Life Sciences, Inc. Registration Statement on Form S-1 File No. 333-276070 Ladies and Gentlemen: TriSalus Life Sciences, Inc. (t |
|
| December 21, 2023 |
TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 TriSalus Life Sciences, Inc. 6272 W. 91st Ave. Westminster, Colorado 80031 December 21, 2023 Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Juan Grana, Abby Adams Re: TriSalus Life Sciences, Inc. Amendment No. 3 to Registration Statement on Form S-1 File No. 333-274292 Ladies and Gentlemen: TriSalus |
|
| December 15, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 15, 2023. Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or o |
|
| December 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) TriSalus Life Sciences, Inc. |
|
| December 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-1/A (Form Type) TriSalus Life Sciences, Inc. |
|
| December 15, 2023 |
As filed with the U.S. Securities and Exchange Commission on December 14, 2023. Table of Contents As filed with the U.S. Securities and Exchange Commission on December 14, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict |
|
| December 14, 2023 |
Carlos Ramirez T: +1 858 550 6157 [email protected] December 14, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.C. 20549 Attention: Nicholas O’Leary Abby Adams Re: TriSalus Life Sciences, Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed October 19, 2023 File No. 333-274292 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 14, 2023 |
Exhibit 99.1 TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net revenues of $12.8 million, up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01 data demo |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 TRISALUS LIFE SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Com |
|
| October 19, 2023 |
As filed with the U.S. Securities and Exchange Commission on October 18, 2023. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 18, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdicti |
|
| October 19, 2023 |
Exhibit 10.14 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [**], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of August 28, 2023 (the “Effective Da |
|
| October 18, 2023 |
Carlos Ramirez T: +1 858 550 6157 [email protected] October 18, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, NE Washington, D.C. 20549 Attention: Nicholas O’Leary Abby Adams Re: TriSalus Life Sciences, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed September 1, 2023 File No. 333-274292 Ladies and Gentlemen: O |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) TriSalus Life Sciences, Inc. |
|
| October 3, 2023 |
STANDBY EQUITY PURCHASE AGREEMENT Exhibit 99.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of October 2, 2023 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and TRISALUS LIFE SCIENCES, INC., a company incorporated under the laws of the State of Delaware (the “Company”). WHEREAS, the parties desire that, upon the terms and |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 1, 2023 |
Exhibit 99.1 1 OUR MISSION : TriSalus Life Sciences seeks to Transform the way liver and pancreatic tumors are treated through our immunotherapeutic and drug delivery technology TriSalus Life Sciences SEPTEMBER 2023 Disclaimer © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 2 Certain statements in this presentation may constitute “forward looking statements” within the meaning of applicable |
|
| September 1, 2023 |
As filed with the U.S. Securities and Exchange Commission on September 1, 2023. Table of Contents As filed with the U.S. Securities and Exchange Commission on September 1, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 31, 2023 |
As filed with the U.S. Securities and Exchange Commission on August 31, 2023. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on August 31, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation |
|
| August 31, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) TriSalus Life Sciences, Inc. |
|
| August 29, 2023 |
TLSI / TriSalus Life Sciences Inc / Unique Diamond Investments Ltd - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TRISALUS LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 89680M101 (CUSIP Number) August 10, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| August 29, 2023 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain common stock, par value $0. |
|
| August 23, 2023 |
TLSI / TriSalus Life Sciences Inc / Lombard International Assurance S.a. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 TriSalus Life Sciences Inc. (Name of Issuer) Common stock (Title of Class of Securities) 89680M101 (CUSIP Number) August 10, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| August 22, 2023 |
TLSI / TriSalus Life Sciences Inc / Stansky Michael P Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TRISALUS LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 89680M101 (CUSIP Number) August 10, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| August 21, 2023 |
TLSI / TriSalus Life Sciences Inc / Dewey Christopher C Passive Investment SC 13G 1 deweysc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TRISALUS LIFE SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 89680M101 (CUSIP Number) August 10, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| August 21, 2023 |
TLSI / TriSalus Life Sciences Inc / Wahlstrom Mats - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* TriSalus Life Sciences, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 89680M 101 (CUSIP Number) Mats Wahlström c/o TriSalus Life Sciences, Inc. 6272 W. 91st Avenue Westminster, CO 80031 Telephone: 72 |
|
| August 21, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D with respect to the beneficial ownership by the undersigned of the securities of TriSalus Life Sciences, Inc. is being filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be file |
|
| August 21, 2023 |
TLSI / TriSalus Life Sciences Inc / MCGREVIN GENE R - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* TriSalus Life Sciences, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 89680M 101 (CUSIP Number) August 10, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to de |
|
| August 21, 2023 |
TLSI / TriSalus Life Sciences Inc / Frankenius Equity AB - SC 13D Activist Investment SC 13D 1 d359872dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* TriSalus Life Sciences, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 89680M 101 (CUSIP Number) Paul Frankenius Frankenius Equity AB Box 984 501 10 Boras Sweden Telephone: |
|
| August 21, 2023 |
TLSI / TriSalus Life Sciences Inc / MATLIN DAVID J - SC 13D Activist Investment SC 13D 1 d359612dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* TriSalus Life Sciences, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 89680M 101 (CUSIP Number) David J. Matlin c/o TriSalus Life Sciences, Inc. 6272 W. 91st Avenue Westmin |
|
| August 16, 2023 |
Exhibit 10.1 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 10, 2023, is made and entered into by and among (i) TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”) (formerly known as MedTech Acquisition Corp. (“MedTech”), a Delaware corporation), (ii) MedTech Acquisition Sponsor LLC, |
|
| August 16, 2023 |
Amended and Restated Bylaws of TriSalus Life Sciences, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF Trisalus life sciences, inc. (A DELAWARE CORPORATION) August 10, 2023 ARTICLE I Offices Section 1. Registered Office. The registered office of TriSalus Life Sciences, Inc. (the “corporation”) in the State of Delaware and the name of the corporation’s registered agent at such address shall be as set forth in the Amended and Restated Certificate o |
|
| August 16, 2023 |
Exhibit 3.3 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A CONVERTIBLE PREFERRED STOCK OF TRISALUS LIFE SCIENCES, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned, pursuant to the provisions of Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that, pursuant to the authority exp |
|
| August 16, 2023 |
Exhibit 99.1 TRISALUS LIFE SCIENCES, INC. Condensed Consolidated Balance Sheets (unaudited, in thousands except share and per share data) June 30, 2023 December 31, 2022 Assets Assets Cash and cash equivalents $ 3,904 $ 9,414 Accounts receivable 2,094 1,557 Inventory, net 1,522 1,471 Prepaid expenses 4,859 4,772 Total current assets 12,379 17,214 Property and equipment, net 1,885 2,231 Right-of-us |
|
| August 16, 2023 |
Exhibit 10.22 TriSalus Life Sciences, Inc. Stock Option Grant Notice (2023 Equity Incentive Plan) TriSalus Life Sciences, Inc. (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (“Option”). Your Option is subject to all of the terms and conditions as set forth h |
|
| August 16, 2023 |
Exhibit 10.20 TriSalus Life Sciences, Inc. 2009 Equity Incentive Plan Notice of Restricted Stock Unit Award 1. You (“Participant”) have been granted Restricted Stock Units (“RSUs”) representing shares of the Common Stock of TriSalus Life Sciences, Inc. (the “Company”) on the following terms: Name of Participant: [ ] Total Number of RSUs Granted: [ ] Date of Grant: [ ] Vesting Start Dat |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 16, 2023 |
Exhibit 10.19 SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES AMENDED AND RESTATED 2009 STOCK OPTION PLAN EARLY EXERCISE STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2009 Stock Option Plan, as amended from time to time (the “Plan”), shall have the same defined meanings in this Early Exercise Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK |
|
| August 16, 2023 |
Exhibit 10.23 TriSalus Life Sciences, Inc. RSU Award Grant Notice (2023 Equity Incentive Plan) TriSalus Life Sciences, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in |
|
| August 16, 2023 |
Letter from WithumSmith+Brown, PC to the SEC, dated August 16, 2023. Exhibit 16.1 August 16, 2023 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read the statements made by TriSalus Life Sciences, Inc. (“TriSalus”) included under Item 4.01 of its Form 8-K dated August 16, 2023. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our di |
|
| August 16, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Capitalized terms used but not defined in this Exhibit 99.3 shall have the meanings ascribed to them in this Current Report on Form 8-K (the “Form 8-K”) and, if not defined in the Form 8-K, the final prospectus and definitive proxy statement, dated July 18, 2023 (the “proxy statement/prospectus”), filed by MedTech Acquisitio |
|
| August 16, 2023 |
Exhibit 99.4 TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation Advances TriSalus’ Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales Growth Advancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Chola |
|
| August 16, 2023 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF TRISALUS LIFE SCIENCES, INC. 1. TriSalus Operating Life Sciences, Inc. |
|
| August 16, 2023 |
Management’s Discussion and Analysis of Financial Condition and Results of Operations of TriSalus Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations of TriSalus The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial statements and the related notes thereto as of June 30, 2023 and for the three and six months ended June 30, 2023 and |
|
| August 16, 2023 |
Exhibit 10.25 TRISALUS LIFE SCIENCES, INC. INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (this “Agreement”) is dated as of , 20 and is between TriSalus Life Sciences, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or off |
|
| August 16, 2023 |
TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan Exhibit 10.24 TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan Adopted by the Board of Directors: August 10, 2023 Approved by the Stockholders: August 8, 2023 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permi |
|
| August 16, 2023 |
Specimen Common Stock Certificate. Exhibit 4.1 NUMBER NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 89680M 101 TRISALUS LIFE SCIENCES, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE COMMON STOCK OF TRISALUS LIFE SCIENCES, INC. (THE “CORPORATION”) transferable on the books of the Corpo |
|
| August 16, 2023 |
Exhibit 10.18 SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES AMENDED AND RESTATED 2009 STOCK OPTION PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2009 Stock Option Plan, as amended from time to time (the “Plan”), shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK OPTION GRANT Grant of Option: |
|
| August 16, 2023 |
Exhibit 10.17 SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES AMENDED AND RESTATED 2009 STOCK OPTION PLAN EARLY EXERCISE STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2009 Stock Option Plan, as amended from time to time (the “Plan”), shall have the same defined meanings in this Early Exercise Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK |
|
| August 16, 2023 |
Exhibit 10.16 SUREFIRE MEDICAL, INC. DBA TRISALUS™ LIFE SCIENCES AMENDED AND RESTATED 2009 STOCK OPTION PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2009 Stock Option Plan, as amended from time to time (the “Plan”), shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”). I. NOTICE OF STOCK OPTION GRANT Name: Address: Th |
|
| August 16, 2023 |
TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan Exhibit 10.21 TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan Adopted by the Board of Directors: August 10, 2023 Approved by the Stockholders: August 8, 2023 1. General. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts fo |
|
| August 16, 2023 |
Exhibit 10.14 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [**], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. TRISALUS LIFE SCIENCES AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT AND ARBITRATION AGREEMENT As a condition of my employment w |
|
| August 16, 2023 |
Exhibit 4.2 [Form of Warrant Certificate] [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW TRISALUS LIFE SCIENCES, INC. Incorporated Under the Laws of the State of Delaware CUSIP 89680M 119 Warrant Certificate This Warrant Certificate certifies that , or registered assigns, is the |
|
| August 16, 2023 |
Surefire Medical, Inc. 2009 Amended and Restated Equity Incentive Plan. Exhibit 10.15 SUREFIRE MEDICAL, INC. 2009 EQUITY INCENTIVE PLAN AS AMENDED 1. Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● to provide additional incentive to Employees, Directors and Consultants, and ● to promote the success of the Company’s business. The Plan permits the grant of Incentive |
|
| August 16, 2023 |
Exhibit 4.4 Description of Common Stock The following description summarizes selected information regarding the common stock, $0.0001 par value per share (the “Common Stock”), of TriSalus Life Sciences, Inc., a Delaware corporation (“TriSalus,” the “Company,” “we,” “us” or “our”), as well as relevant provisions of: (i) our Second Amended and Restated Certificate of Incorporation (“Certificate of I |
|
| August 16, 2023 |
Second Amended and Restated Certificate of Incorporation of TriSalus Life Sciences, Inc. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MEDTECH ACQUISITION CORPORATION MedTech Acquisition Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is “MedTech Acquisition Corporation” (the “Corporation”). The original ce |
|
| August 16, 2023 |
Non-Employee Director Compensation Policy. Exhibit 10.26 TriSalus Life Sciences, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to TriSalus Life Sciences, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy |
|
| August 14, 2023 |
MedTech Acquisition Corp/NY / Magnetar Financial LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* MedTech Acquisition Corp** (Name of Issuer) Common Stock - Class A (Title of Class of Securities) 58507N105 (CUSIP Number of Class of Securities) David J. Snyderman Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Name, A |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 MedTech Acquisition Corporation (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporati |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 MedTech Acquisition Corporation (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporati |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 MedTech Acquisition Corporation (Exact name of registrant as specified in its charter) Delaware 001-39813 85-3009869 (State or other jurisdiction of incorporati |
|
| August 2, 2023 |
MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders Exhibit 99.1 MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders NEW YORK, August 2, 2023 – MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or the “Company”) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the “Special Meeting”). The Special Meeting is being held to vote on certain proposals r |
